POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER).
Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.
| Metabolism | Potassium is not metabolized; it is excreted primarily by the kidneys. Dextrose undergoes glycolysis and oxidation to carbon dioxide and water. |
| Excretion | Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion; fecal: <10%; minor sweat losses. In this formulation (KCl 0.22% in D5W), the potassium content is 2 mEq per 100 mL (approximately 20 mEq/L). |
| Half-life | The elimination half-life of potassium is not applicable in the traditional sense because potassium is an endogenous ion under tight homeostatic control. After intravenous infusion of a potassium load, the plasma concentration declines with a distribution phase of about 1-2 hours, followed by a slower elimination phase reflecting cellular uptake and renal excretion, with a terminal half-life of approximately 6-8 hours in patients with normal renal function. |
| Protein binding | Negligible (<5%). Potassium is not significantly bound to plasma proteins; it exists as free ion in serum. |
| Volume of Distribution | Approximately 0.5-0.6 L/kg (total body water); reflects distribution throughout extracellular and intracellular spaces. Potassium is predominantly intracellular (98% of total body potassium is in cells); Vd for administered potassium is large due to cellular uptake. |
| Bioavailability | Intravenous: 100% (complete bioavailability). Oral: about 90% absorbed; however, this formulation is for IV administration only. |
| Onset of Action | Intravenous: Correction of hypokalemia begins within minutes after starting infusion; clinical effect (e.g., improvement in muscle weakness, ECG changes) seen within 30-60 minutes at appropriate infusion rates (usual rate: 10-20 mEq/h; max 40 mEq/h with cardiac monitoring). |
| Duration of Action | Intravenous: Effect persists for the duration of infusion and several hours thereafter; potassium levels gradually return to baseline over 6-12 hours post-infusion, depending on ongoing losses and cellular uptake. Continuous infusion required for sustained correction of severe depletion. |
| Molecular Weight | 74.55 |
Intravenous; typical adult dose is 10-20 mEq/hour, not exceeding 40 mEq/hour or 150 mEq/day, with continuous cardiac monitoring and serum potassium monitoring.
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: no adjustment; GFR 10-50 mL/min: reduce total daily dose by 25-50%; GFR < 10 mL/min: reduce dose by 50-75% and monitor potassium closely. Avoid if anuria. |
| Liver impairment | No specific adjustment based on Child-Pugh score; however, monitor potassium levels and renal function closely due to potential hepatorenal syndrome. |
| Pediatric use | Intravenous; 0.2-0.5 mEq/kg/hour, not exceeding 1 mEq/kg/hour or 40 mEq/m²/hour; adjust based on serum potassium and clinical status. |
| Geriatric use | Cautious dosing: initial dose at lower end of adult range (10 mEq/hour) with close monitoring of renal function and serum potassium due to decreased renal reserve and higher risk of hyperkalemia. |
| 1st trimester | Potassium chloride and dextrose are generally considered safe in pregnancy when used as electrolyte replacement. No teratogenic effects reported at therapeutic doses. |
| 2nd trimester | Safe for use in pregnancy. May be used to correct hypokalemia. Dextrose provides calories and may be beneficial in hyperemesis. |
| 3rd trimester | Safe for use in pregnancy. Monitor maternal electrolytes and fetal well-being if used for prolonged periods or in high doses. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Placental transfer | Potassium crosses the placenta via active transport. Dextrose crosses easily. Both are physiologic substances. |
| Breastfeeding | Potassium chloride and dextrose are normal constituents of breast milk. Use during breastfeeding is considered safe. No adverse effects in infants reported from maternal infusion. |
| Lactation Rating | L1 (safest) |
| Teratogenic Risk | Potassium chloride and dextrose are not known to be teratogenic. No fetal risks have been identified in any trimester. Dextrose is a physiological nutrient. Overdose or rapid infusion may cause maternal electrolyte imbalance potentially affecting fetus. |
| Fetal Monitoring | Monitor serum potassium and glucose levels, fluid balance, and renal function. Monitor fetal heart rate during infusion if indicated. |
| Fertility Effects | No known adverse effects on fertility. |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia.
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaAddison's diseaseHyperchloremiaMetabolic alkalosis
| Precautions | Hyperkalemia risk; monitor serum potassium levels, Cardiotoxicity; ECG monitoring recommended, Risk of extravasation; do not administer intramuscularly, Use with caution in renal impairment, adrenal insufficiency, or conditions predisposing to hyperkalemia, Do not administer if solution is discolored or contains particulate matter |
| Food/Dietary | Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, salt substitutes) while receiving this IV solution to prevent hyperkalemia. |
| Clinical Pearls | This solution provides 22 mEq/L of potassium chloride and 5% dextrose. Use with caution in patients with renal impairment, cardiac disease, or hyperkalemia. Monitor serum potassium levels closely; rate of infusion should not exceed 10 mEq/hour typically. Avoid in patients with oliguria or anuria. Do not administer undiluted; container is for intravenous use only. |
| Patient Advice | This medication is given through a vein to provide potassium and sugar. · Tell your healthcare provider if you have kidney problems, heart disease, or are taking any other medications. · Report any symptoms of high potassium such as muscle weakness, irregular heartbeat, or tingling sensations. · You may experience pain or irritation at the IV site; inform your nurse if this occurs. · Do not stop or change the infusion rate on your own. |
Loading safety data…